Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$51.73 USD

51.73
1,388,647

+0.47 (0.92%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $51.74 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Shilpa Mete headshot

Alphabet's Healthcare Push Gains Steam: Others Brace Up

by Shilpa Mete

Alphabet's (GOOGL) Google's partnership with Sanofi provides it a competitive edge in the healthcare sector.

Sanofi Partners Google to Build Healthcare Innovation Lab

by Zacks Equity Research

Sanofi (SNY) signs a partnership pact with Google to develop a new virtual healthcare innovation lab for modernizing future medicines and healthcare services with sophisticated data technologies.

Protalix (PLX) Completes Enrollment in Fabry Disease Study

by Zacks Equity Research

Protalix (PLX) closes enrollment in the late-stage study on PRX-102, currently being developed for the treatment of patients with Fabry disease.

Novo Nordisk's Victoza Gets FDA Nod for Pediatric Patients

by Zacks Equity Research

Novo Nordisk's (NVO) Victoza gets FDA approval for the treatment of pediatric patients aged 10 years or older with type II diabetes.

Regeneron (REGN) Presents Positive Data on Lymphoma Candidate

by Zacks Equity Research

Regeneron (REGN) reports positive early-stage data on REGN1979 in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma.

Kinjel Shah headshot

Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod

by Kinjel Shah

Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.

Lilly Announces Tradjenta Cardiovascular Outcome Study Data

by Zacks Equity Research

Tradjenta leads to fewer events of hypoglycemia and modest weight reduction in type II diabetes patients compared to Sanofi's Amaryl.

Sanofi (SNY) in Focus: Stock Moves 5.5% Higher

by Zacks Equity Research

Sanofi (SNY) shares rose nearly 6% in the last trading session, amid huge volumes.

Kinjel Shah headshot

Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache

by Kinjel Shah

Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.

Novartis Appoints New Pharma Unit Head, Gives Other Updates

by Zacks Equity Research

Novartis (NVS) appoints Marie-France Tschudin as head of the pharma unit. The company also provides a few pipeline updates.

Kinjel Shah headshot

Was ASCO Quieter for Big Drug/Biotech Stocks This Year?

by Kinjel Shah

The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.

Glaxo's Nucala Gets CHMP Nod for 2 Self-Administered Options

by Zacks Equity Research

GlaxoSmithKline (GSK) announces that the EMA???s Committee for Medicinal Products for Human Use has issued a positive opinion for two self-administered options of its asthma drug, Nucala.

Emergent (EBS) Wins HHS Contract to Supply VIGIV Product

by Zacks Equity Research

Shares of Emergent (EBS) rise after the company gets a 10-year HHS contract valued at roughly $535 million to dispense VIGIV product to the U.S. government for supporting its smallpox awareness drive.

Amarin Rises on Priority Review for Vascepa Label Expansion

by Zacks Equity Research

Amarin's (AMRN) label expansion application for hypertriglyceridemia drug, Vascepa, gets priority review from the FDA.

BioMarin Announces Data on Hemophilia Candidate, Shares Fall

by Zacks Equity Research

BioMarin (BMRN) announces significant reduction in annual bleed rate in phase III study evaluating gene therapy, valoctocogene roxaparvovec, in hemophilia A patients. However, investors are skeptical.

Alphabet to Aid Pharma Giants Enhance Clinical Trial Process

by Zacks Equity Research

Alphabet's (GOOGL) Verily joins hands with Novartis, Sanofi, Otsuka and Pfizer to revolutionize the clinical trial methods.

Lilly (LLY) Launches Half-Priced Version of Humalog Insulin

by Zacks Equity Research

Eli Lilly (LLY) offers a cheaper version of its popular insulin, Humalog amid increasing pressure to lower drug costs.

Pfizer's Eczema Candidate Meets All Goals in Phase III Study

by Zacks Equity Research

Pfizer's (PFE) investigational eczema treatment abrocitinib succeeds in pivotal late-stage study.

Inovio (INO) Q1 Earnings & Revenues Fall Short of Estimates

by Zacks Equity Research

Inovio Pharmaceuticals' (INO) earnings and revenues disappoint with an estimate miss in the first quarter. Shares slip in after-hours trading.

Regeneron (REGN) Stock Down on Earnings, Sales Miss in Q1

by Zacks Equity Research

Regeneron's (REGN) first-quarter performance was dismal with the company missing on both earnings and sales estimates.

The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo

Emergent (EBS) Earnings & Revenues Miss Estimates in Q1

by Zacks Equity Research

Emergent (EBS) incurs loss in the first quarter and misses on revenues as well.

Kinjel Shah headshot

Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV Drugs Get EU Nod

by Kinjel Shah

Merck (MRK), Pfizer (PFE), Lilly (LLY) announce Q1 results. European Commission grants approval to AbbVie's (ABBV) Skyrizi and Sanofi's (SNY) Zynquista.

Alnylam (ALNY) Reports Narrower-Than-Expected Loss in Q1

by Zacks Equity Research

Alnylam (ALNY) reports narrower-than-expected loss in the first quarter of 2019. Also, sales beat estimates.

What's in the Cards for Novavax (NVAX) This Earnings Season?

by Zacks Equity Research

Novavax (NVAX) is likely to provide update on the path forward for its two lead vaccine candidates.